Andrzej Łabyk

Dr. Andrzej Łabyk

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2019 in Polish Heart Journal
Verified
Journal Article
Open access
PDF file
MRMarek Roik
Marek Roik
DWDominik Wretowski
Dominik Wretowski
AŁAndrzej Łabyk
Andrzej Łabyk
MCMichał Ciurzyński
Michał Ciurzyński
KKKatarzyna Kurnicka
Katarzyna Kurnicka
PPPiotr Pruszczyk
Piotr Pruszczyk

12 April 2010 in Annals of Noninvasive Electrocardiology
Verified
Journal Article
Closed access
PDF file
KJKrzysztof Jankowski
Krzysztof Jankowski
MKMaciej Kostrubiec
Maciej Kostrubiec
POPatrycja Ozdowska
Patrycja Ozdowska
BMBlanka Milanowska‐Puncewicz
Blanka Milanowska‐Puncewicz
SPSzymon Pacho
Szymon Pacho
PPPiotr Pruszczyk
Piotr Pruszczyk

16 August 2018 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
AŁAndrzej Łabyk
Andrzej Łabyk
DWDominik Wretowski
Dominik Wretowski
SZSabina Zybińska-Oksiutowicz
Sabina Zybińska-Oksiutowicz
AFAleksandra Furdyna
Aleksandra Furdyna
KCKatarzyna Ciesielska
Katarzyna Ciesielska
MRMarek Roik
Marek Roik
Approximately a quarter of patients with advanced sarcoidosis develop pulmonary hypertension (PH), which affects their prognosis. We report unusual case of confirmed chronic thromboembolic pulmonary hypertension (CTEPH) in a patient with stage IV sarcoidosis successfully treated with balloon pulmonary angioplasty (BPA). A 65 years old male with a history of colitis ulcerosa, and pulmonary sarcoidosis diagnosed in 10 years before, on long term oral steroids, with a history of deep vein thrombosis and acute pulmonary embolism chronically anticoagulated was referred to our center due to severe dyspnea. On admission he presented WHO functional class IV, mean pulmonary artery pressure (mPAP) in right heart catheterization (RHC) was elevated to 54 mmHg. Diagnosis of CTEPH was definitely confirmed with typical V/Q scan, and with selective pulmonary angiography (PAG) completes by intravascular imagining (intravascular ultrasound, optical coherent tomography). The patient was deemed inoperable by CTEPH team and two sessions of BPA with multimodal approach resulted in significant clinical and haemodynamical improvement to WHO class II and mPAP decrease to 27 mmHg. Balloon pulmonary angioplasty, rapidly developing method of treatment of inoperable CTEPH patients, is also extremely useful therapeutic tool in complex PH patients.

1 January 2021 in Advances in Interventional Cardiology
Verified
Journal Article
Open access
AŁAndrzej Łabyk
Andrzej Łabyk
MPMichał Potępa
Michał Potępa
MJMateusz Jermakow
Mateusz Jermakow
MMMichał Machowski
Michał Machowski
PPPiotr Pruszczyk
Piotr Pruszczyk
MRMarek Roik
Marek Roik
Percutaneous pulmonary embolectomy (PPE) is a rapidly evolving therapy in selected acute pulmonary embolism (APE) patients [1–5]. Novel percutaneous procedures tend not to be common, even in reference centers.

22 January 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MJMateusz Jermakow
Mateusz Jermakow
MMMichał Machowski
Michał Machowski
MGMagdalena Gałecka-Nowak
Magdalena Gałecka-Nowak
DDDeutsch Deutsch
Deutsch Deutsch
AIAdam Il
Adam Il
PPPiotr Pruszczyk
Piotr Pruszczyk
Background: The primary role of a pulmonary embolism response team (PERT) is to support decision-making processes regarding acute pulmonary embolism (PE) patients and provide advanced rescue therapies when needed. Despite a great need for its availability among physicians, PERT’s usefulness is yet to be proven. Objectives: Our goal was to establish whether patients benefit from qualification by PERT for admission to a tertiary cardiology ward. Methods: Data of all patients hospitalized due to PE for 12 months (July 2023–June 2024) were retrospectively analyzed. We aimed to compare patients admitted primarily via the emergency department with those consulted by PERT and eventually transferred from other hospitals. The primary outcome was the use of advanced therapies. Results: We identified 167 patients (50.3% women) hospitalized with PE. Out of them, 102 (61.1%) came from the emergency department, while 65 (38.9%) patients were transferred after PERT consultation. The transferred patients generally had more severe conditions, as indicated by the ESC death risk group classification (intermediate-high and high risk, OR 19.2, 95% CI 8.3–44.2). They were more often qualified for at least one of the advanced therapies than the emergency department patients (OR 23.2, 95% CI 9.3–58.1). We found no significant differences in in-hospital mortality (6.9% versus 1.5%, OR 4.7, 95% CI 0.6–39.3). Conclusions: Establishing PERT as a reference unit providing advanced treatment resulted in successfully delivering more complex treatment to severely ill PE patients. Despite their unfavorable basic characteristics, neither length of hospitalization nor in-hospital mortality seem to differ when compared to unselected, less compromised cases.

10 April 2024 in Medical Science Monitor
Verified
Journal Article
Open access
MMMichał Machowski
Michał Machowski
AOAisha Ou-Pokrzewińska
Aisha Ou-Pokrzewińska
KPKatarzyna Perzanowska-Brzeszkiewicz
Katarzyna Perzanowska-Brzeszkiewicz
MGMagdalena Gałecka-Nowak
Magdalena Gałecka-Nowak
SPSzymon Pacho
Szymon Pacho
PPPiotr Pruszczyk
Piotr Pruszczyk
Background: COVID-19 increases the risk of acute cardiovascular diseases (CVDs), including acute coronary syndrome (ACS), acute pulmonary embolism (APE), and acute myocarditis (AMyo). The actual impact of CVDs on mortality of patients with COVID-19 remains unknown. This study aimed to determine whether CVDs influence the course of COVID-19 pneumonia and if they can be easily detected by using common tests and examinations. Material/Methods: Data of 249 consecutive patients with COVID-19 hospitalized in a dedicated cardiology department were analyzed. On admission, clinical status, biomarkers, computed tomography, and bedside echocardiography were performed. Results: D-dimer level predicted APE (AUC=0.850 95% CI [0.765; 0.935], P <0.001) with sensitivity of 69.4% and specificity of 96.2% for a level of 4968.0 ng/mL, and NT-proBNP predicted AMyo (AUC=0.692 95% CI [0.502; 0.883], P =0.004) and showed sensitivity of 54.5%, with specificity of 86.5% for the cut-off point of 8970 pg/mL. Troponin T levels were not useful for diagnostic differentiation between CVDs. An extent of lung involvement predicted mortality (OR=1.03 95% CI [1.01;1.04] for 1% increase, P <0.001). After adjusting for lung involvement, ACS increased mortality, compared with COVID-19 pneumonia only (OR=5.27 95% CI [1.76; 16.38] P =0.003), while APE and AMyo did not affect risk for death. Conclusions: D-dimer and NT-proBNP, but not troponin T, are useful in differentiating CVDs in patients with COVID-19. ACS with COVID-19 increased in -hospital mortality independently from extent of lung involvement, while coexisting APE or AMyo did not.